CoMind
PrivateLast Round
Series A
Extension
Oct 20, 2025
Total Funding Raised
$102.5M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
CoMind operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Series A Extension round in October 2025.
CoMind is a neurotechnology company that develops non-invasive brain-computer interfaces and optical neuromonitoring devices designed to monitor neurological parameters and improve patient outcomes.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Medical AI, Clinical Trials, Sensors
Business Model
B2B
Customer Profile
Hardware Sales, Hardware + Subscription
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
CoMind Comparables
Compare CoMind with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kernel | 84% | |
| Emotiv | 78% | |
| Artinis Medical Systems | 77% |
For institutional investors. Book with your work email.
CoMind Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Oct 20, 2025 | ||||
| Series A | Nov 1, 2023 | ||||
| Grant | Jan 6, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
CoMind Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Backed VC | Series A Extension |
| LocalGlobe | Series A Extension |
| Latitude Ventures | Series A Extension |
| Angelini Ventures | Series A Extension, Series A |
| Phoenix Court Group | Series A Extension, Seed |
| LocalGlobe | Series A Extension |
| Thiel Fellowship | Grant |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 30% MoM, reaching 9.7K.
- Mar 30, 2026
Neuromonitoring tech in clinical trials, developing FDA software.
For institutional investors. Book with your work email.
CoMind Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about CoMind's valuation, stock price, and market status.
Is CoMind a public or private company?
CoMind is a private company.
What is the current stock price of CoMind?
CoMind is a private company, so its shares have no public market price. Caplight tracks CoMind's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is CoMind worth (valuation)?
Valuation information for CoMind is not publicly available.
Can I buy CoMind stock?
CoMind shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was CoMind's last funding round?
CoMind's most recent funding round was Series A Extension on October 20, 2025.
Who are the main investors in CoMind?
Key investors in CoMind include Angelini Ventures, Phoenix Court Group, Octopus Ventures, Plural.
Will CoMind IPO soon?
No public IPO plans have been announced for CoMind.
How can I track CoMind secondary market activity?
Caplight tracks bids, offers, and trades in CoMind's shares on secondary markets.